Needham & Company reiterates a 'Buy' on Æterna Zentaris (AEZS); Newly Issued Use Patent Provides L-T Protection for Perifosine in the EU
Tweet
Share
E-mailGet Alerts AEZS Hot Sheet
Price: $5.72 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Needham & Company reiterates a 'Buy' on Æterna Zentaris (NASDAQ: AEZS), PT $5.
Needham analyst says, "This morning, AEZS announced that the European Patent Office has granted a patent for the use of perifosine in combination with anti-tumor anti-metabolites for the treatment of benign and malignant tumors. The patent expires on July 28, 2023 and covers broad applications of perifosine for use in combination treatment for cancer. Similar patent applications have been granted in certain other countries and are under review in the US. We are encouraged by the patent issuance that extends perifosine patent life by an extra 10 years beyond the expiration of the composition patent in 2013."
"In the long-term, we believe the Company’s solid science platform, built on its expertise on kinase inhibitors, has matured and may generate additional product candidates for internal development as well as external collaborations."
For more ratings news on Æterna Zentaris click here and for the rating history of Æterna Zentaris click here.
Shares of Æterna Zentaris closed at $2.27 yesterday.
Needham analyst says, "This morning, AEZS announced that the European Patent Office has granted a patent for the use of perifosine in combination with anti-tumor anti-metabolites for the treatment of benign and malignant tumors. The patent expires on July 28, 2023 and covers broad applications of perifosine for use in combination treatment for cancer. Similar patent applications have been granted in certain other countries and are under review in the US. We are encouraged by the patent issuance that extends perifosine patent life by an extra 10 years beyond the expiration of the composition patent in 2013."
"In the long-term, we believe the Company’s solid science platform, built on its expertise on kinase inhibitors, has matured and may generate additional product candidates for internal development as well as external collaborations."
For more ratings news on Æterna Zentaris click here and for the rating history of Æterna Zentaris click here.
Shares of Æterna Zentaris closed at $2.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Pulse Biosciences (PLSE) at Buy
- Deutsche Bank Downgrades SentinelOne Inc (S) to Hold on Valuation
- B.Riley Downgrades Lantheus Holdings (LNTH) to Neutral
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
